Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Hay-fever drug banned in the US

Liz Hunt
Friday 24 January 1997 00:02 GMT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A hay-fever drug which is widely used in Britain is to be banned in the United States after 17 deaths and 40 cases of serious heart problems associated with it.

The drug terfenadine is sold under the names Triludan and Seldane, and is popular because it is non-sedative, unlike other hay-fever remedies with anti-histamine action.

It has been available since the mid-1980s in the US and in the UK but in 1992 the drug authorities became aware of potentially fatal effects on heart rhythm when the drug was taken at the same time as certain antibiotics. People with liver disease are also vulnerable. The UK Committee on Safety of Medicines says it is aware of the FDA's action but has no plans to follow suit. The drug's manufacturer in the US, Hoechst Marion Roussel, says it will challenge the decision, and that terfenadine is safe when prescribed properly in appropriate patients.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in